Abstract
Typhoid fever is an invasive bacterial disease associated with bloodstream infection that causes a high burden of disease in Africa and Asia. Typhoid primarily affects individuals ranging from infants through to young adults. The causative organism, Salmonella enterica subsp. enterica serovar Typhi is transmitted via the faecal–oral route, crossing the intestinal epithelium and disseminating to systemic and intracellular sites, causing an undifferentiated febrile illness. Blood culture remains the practical reference standard for diagnosis of typhoid fever, where culture testing is available, but novel diagnostic modalities are an important priority under investigation. Since 2017, remarkable progress has been made in defining the global burden of both typhoid fever and antimicrobial resistance; in understanding disease pathogenesis and immunological protection through the use of controlled human infection; and in advancing effective vaccination programmes through strategic multipartner collaboration and targeted clinical trials in multiple high-incidence priority settings. This Primer thus offers a timely update of progress and perspective on future priorities for the global scientific community.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 1 digital issues and online access to articles
$99.00 per year
only $99.00 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dougan, G. & Baker, S. Salmonella enterica serovar Typhi and the pathogenesis of typhoid fever. Annu. Rev. Microbiol. 68, 317–336 (2014).
World Health Organization. Typhoid: vaccine preventable diseases surveillance standards. WHO https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-typhoid (2018).
Basnyat, B., Qamar, F. N., Rupali, P., Ahmed, T. & Parry, C. M. Enteric fever. BMJ 372, n437 (2021).
Von Drigalski, K. W. Ueber Ergebnisse bei der Bekämpfung des Typhus nach Robert Koch [German]. Zentralbl. Bakteriol. 35, 776 (1904).
Kirchhelle, C., Pollard, A. J. & Vanderslott, S. Typhoid – from past to future. Clin. Infect. Dis. 69, S375–s376 (2019).
Ames, W. R. & Robins, M. Age and sex as factors in the development of the typhoid carrier state, and a method for estimating carrier prevalence. Am. J. Public. Health Nations Health 33, 221–230 (1943).
Antillon, M., Saad, N. J., Baker, S., Pollard, A. J. & Pitzer, V. E. The relationship between blood sample volume and diagnostic sensitivity of blood culture for typhoid and paratyphoid fever: a systematic review and meta-analysis. J. Infect. Dis. 218, S255–S267 (2018).
Nizamuddin, S., Khan, E. A., Chattaway, M. A. & Godbole, G. Case of carbapenem-resistant Salmonella Typhi infection, Pakistan, 2022. Emerg. Infect. Dis. J. 29, 2395–2397 (2023).
Phillips, M. T., Owers, K. A., Grenfell, B. T. & Pitzer, V. E. Changes in historical typhoid transmission across 16 U.S. cities, 1889-1931: quantifying the impact of investments in water and sewer infrastructures. PLoS Negl. Trop. Dis. 14, e0008048 (2020).
Vanderslott, S., Phillips, M. T., Pitzer, V. E. & Kirchhelle, C. Water and filth: reevaluating the first era of sanitary typhoid intervention (1840-1940). Clin. Infect. Dis. 69, S377–S384 (2019).
GBD 2017 Typhoid and Paratyphoid Collaborators The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect. Dis. 19, 369–381 (2019).
Crump, J. A. Progress in typhoid fever epidemiology. Clin. Infect. Dis. 68, S4–S9 (2019).
Appiah, G. D. et al. Typhoid outbreaks, 1989-2018: implications for prevention and control. Am. J. Trop. Med. Hyg. 102, 1296–1305 (2020).
Reller et al. Presented at the 39th Annual Meeting of the Infectious Diseases Society of America (2022).
Mitscherlich, E. & Marth, E. H. Microbial survival in the environment (eds Mitscherlich, E. & Marth E.H.) 1–560 (Springer, 1984).
Cho, J.-C. & Kim, S. J. Viable, but non-culturable, state of a green fluorescence protein-tagged environmental isolate of Salmonella Typhi in groundwater and pond water. FEMS Microbiol. Lett. 170, 257–264 (1999).
Kingsley, R. A. et al. Functional analysis of Salmonella Typhi adaptation to survival in water. Env. Microbiol. 20, 4079–4090 (2018).
Andrews, J. R. et al. Environmental surveillance as a tool for identifying high-risk settings for typhoid transmission. Clin. Infect. Dis. 71, S71–S78 (2020).
Deen, J. et al. Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect. Dis. 12, 480–487 (2012).
Reddy, E. A., Shaw, A. V. & Crump, J. A. Community acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect. Dis. 10, 417–432 (2010).
Marchello, C. S., Dale, A. P., Pisharody, S., Rubach, M. P. & Crump, J. A. Prevalence of community-onset bloodstream infections among hospitalized patients in Africa and Asia: a systematic review and meta-analysis. Antimicrob. Agents Chemother. 64, e01974-19 (2019).
Garrett, D. O. et al. Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: results of the Surveillance for Enteric Fever in Asia Project. Lancet Glob. Health 10, e978–e988 (2022).
Marks, F. et al. The Severe Typhoid in Africa Program: incidences of typhoid fever in Burkina Faso, Democratic Republic of Congo, Ethiopia, Ghana, Madagascar, and Nigeria. Preprint at https://ssrn.com/abstract=4292849 (2022).
Marks, F. et al. Incidence of invasive Salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob. Health 5, e310–e323 (2017).
Meiring, J. E. et al. Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. Lancet Glob. Health 9, e1688–e1696 (2021).
John, J. et al. Burden of typhoid and paratyphoid fever in India. N. Engl. J. Med. 388, 1491–1500 (2023).
Crump, J. A., Luby, S. P. & Mintz, E. D. The global burden of typhoid fever. Bull. World Health Organ. 82, 346–353 (2004).
Antillón, M. et al. The burden of typhoid fever in low- and middle-income countries: a meta-regression approach. PLoS Negl. Trop. Dis. 11, e0005376 (2017).
Mogasale, V. et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob. Health 2, e570–e580 (2014).
Buckle, G. C., Walker, C. L. & Black, R. E. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J. Glob. Health 2, 10401 (2012).
Institute of Health Metrics and Evaluation. Global incidence of typhoid fever. IHME https://vizhub.healthdata.org/gbd-compare/ (2019).
Crump, J. A. & Kirk, M. D. Estimating the burden of febrile illnesses. PLoS Negl. Trop. Dis. 9, e0004040 (2015).
Marchello, C. S., Hong, C. Y. & Crump, J. A. Global typhoid fever incidence: a systematic review and meta-analysis. Clin. Infect. Dis. 68, S105–S116 (2019).
Crump, J. A. et al. Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. Emerg. Infect. Dis. 9, 539–544 (2003).
Marchello, C. S., Birkhold, M. & Crump, J. A. Complications and mortality of typhoid fever: a global systematic review and meta-analysis. J. Infect. 81, 902–910 (2020).
Gibani, M. M. et al. Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model. PLoS Negl. Trop. Dis. 14, e0008783 (2020).
Im, J. et al. Protection conferred by typhoid fever against recurrent typhoid fever in urban Kolkata. PLoS Negl. Trop. Dis. 14, e0008530 (2020).
Brockett, S. et al. Associations among water, sanitation, and hygiene, and food exposures and typhoid fever in case-control studies: a systematic review and meta-analysis. Am. J. Trop. Med. Hyg. 103, 1020–1031 (2020).
Tadesse, B. T. et al. Prevention of typhoid by Vi conjugate vaccine and achievable improvements in household water, sanitation, and hygiene: evidence from a cluster-randomized trial in Dhaka, Bangladesh. Clin. Infect. Dis. 75, 1681–1687 (2022).
Gunn, J. S. et al. Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence. Trends Microbiol. 22, 648–655 (2014).
Dunstan, S. J. et al. Variation at HLA-DRB1 is associated with resistance to enteric fever. Nat. Genet. 46, 1333–1336 (2014).
Saad, N. J. et al. Seasonal dynamics of typhoid and paratyphoid fever. Sci. Rep. 8, 6870 (2018).
Thindwa, D., Chipeta, M. G., Henrion, M. Y. R. & Gordon, M. A. Distinct climate influences on the risk of typhoid compared to invasive non-typhoid Salmonella disease in Blantyre, Malawi. Sci. Rep. 9, 20310 (2019).
Levy, K., Smith, S. M. & Carlton, E. J. Climate change impacts on waterborne diseases: moving toward designing interventions. Curr. Env. Health Rep. 5, 272–282 (2018).
Gao, Q. et al. Impact of temperature and rainfall on typhoid/paratyphoid fever in Taizhou, China: effect estimation and vulnerable group identification. Am. J. Trop. Med. Hyg. 106, 532–542 (2021).
Hickman-Brenner, F. W. & Farmer, J. J. III Bacteriophage types of Salmonella typhi in the United States from 1974 through 1981. J. Clin. Microbiol. 17, 172–174 (1983).
Chattaway, M. A., Langridge, G. C. & Wain, J. Salmonella nomenclature in the genomic era: a time for change. Sci. Rep. 11, 7494 (2021).
Wong, V. K. et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. Nat. Genet. 47, 632–639 (2015).
Tanmoy, A. M. et al. Paratype: a genotyping tool for Salmonella Paratyphi A reveals its global genomic diversity. Nat. Commun. 13, 7912 (2022).
Kariuki, S. et al. Multiple introductions of multidrug-resistant typhoid associated with acute infection and asymptomatic carriage, Kenya. Elife 10, e67852 (2021).
Dyson, Z. A. et al. Genomic epidemiology and antimicrobial resistance transmission of Salmonella Typhi and Paratyphi A at three urban sites in Africa and Asia. Preprint at medRxiv https://doi.org/10.1101/2023.03.11.23286741 (2023).
Wong, V. K. et al. An extended genotyping framework for Salmonella enterica serovar Typhi, the cause of human typhoid. Nat. Commun. 7, 12827 (2016).
Dyson, Z. A. & Holt, K. E. Five years of GenoTyphi: updates to the Global Salmonella Typhi Genotyping Framework. J. Infect. Dis. 224, S775–S780 (2021).
Carey, M. E. et al. Global diversity and antimicrobial resistance of typhoid fever pathogens: insights from a meta-analysis of 13,000 Salmonella Typhi genomes. eLife 12, e85867 (2023).
da Silva, K. E. et al. The international and intercontinental spread and expansion of antimicrobial-resistant Salmonella Typhi: a genomic epidemiology study. Lancet Microbe 3, e567–e577 (2022).
Park, S. E. et al. The phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. Nat. Commun. 9, 5094 (2018).
Guevara, P. D. et al. A genomic snapshot of Salmonella enterica serovar Typhi in Colombia. PLoS Negl. Trop. Dis. 15, e0009755 (2021).
Maes, M. et al. Whole genome sequence analysis of Salmonella Typhi provides evidence of phylogenetic linkage between cases of typhoid fever in Santiago, Chile in the 1980s and 2010–2016. PLoS Negl. Trop. Dis. 16, e0010178 (2022).
Sikorski, M. J. et al. Persistence of rare Salmonella Typhi genotypes susceptible to first-line antibiotics in the remote islands of Samoa. mBio 13, e0192022 (2022).
Davies, M. R. et al. Genomic epidemiology of Salmonella Typhi in central division, Fiji, 2012 to 2016. Lancet Reg. Health West. Pac. 24, 100488 (2022).
Wirth, T. Massive lineage replacements and cryptic outbreaks of Salmonella Typhi in eastern and southern Africa. Nat. Genet. 47, 565–567 (2015).
Gibani, M. M., Britto, C. & Pollard, A. J. Typhoid and paratyphoid fever: a call to action. Curr. Opin. Infect. Dis. 31, 440–448 (2018).
Johnson, R., Mylona, E. & Frankel, G. Typhoidal Salmonella: distinctive virulence factors and pathogenesis. Cell Microbiol. 20, e12939 (2018).
McClelland, M. et al. Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid. Nat. Genet. 36, 1268–1274 (2004).
Parkhill, J. et al. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature 413, 848–852 (2001).
Holt, K. E. et al. High-throughput bacterial SNP typing identifies distinct clusters of Salmonella Typhi causing typhoid in Nepalese children. BMC Infect. Dis. 10, 144 (2010).
Hiyoshi, H., Tiffany, C. R., Bronner, D. N. & Bäumler, A. J. Typhoidal Salmonella serovars: ecological opportunity and the evolution of a new pathovar. FEMS Microbiol. Rev. 42, 527–541 (2018).
Rogers, A. W. L., Tsolis, R. M. & Bäumler, A. J. Salmonella versus the microbiome. Microbiol. Mol. Biol. Rev. 85, e00027-19 (2021).
Bronner, D. N. et al. Genetic ablation of butyrate utilization attenuates gastrointestinal Salmonella disease. Cell Host Microbe 23, 266–273.e4 (2018).
Winter, S. E. et al. The flagellar regulator TviA reduces pyroptosis by Salmonella enterica serovar Typhi. Infect. Immun. 83, 1546–1555 (2015).
Pickard, D. et al. Composition, acquisition, and distribution of the Vi exopolysaccharide-encoding Salmonella enterica pathogenicity island SPI-7. J. Bacteriol. 185, 5055–5065 (2003).
Ménard, S. et al. Cross-talk between the intestinal epithelium and Salmonella typhimurium. Front. Microbiol. 13, 906238 (2022).
Dillon, A. & Lo, D. D. M cells: intelligent engineering of mucosal immune surveillance. Front. Immunol. 10, 1499 (2019).
Watson, K. G. & Holden, D. W. Dynamics of growth and dissemination of Salmonella in vivo. Cell Microbiol. 12, 1389–1397 (2010).
Hart, P. J. et al. Differential killing of Salmonella enterica serovar Typhi by antibodies targeting Vi and lipopolysaccharide O:9 antigen. PLoS ONE 11, e0145945 (2016).
Waddington, C. S. et al. An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution. Clin. Infect. Dis. 58, 1230–1240 (2014).
Waddington, C. S. et al. Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies. J. Infect. 68, 405–418 (2014).
Dobinson, H. C. et al. Evaluation of the clinical and microbiological response to Salmonella Paratyphi a infection in the first paratyphoid human challenge model. Clin. Infect. Dis. 64, 1066–1073 (2017).
Darton, T. C. et al. Blood culture-PCR to optimise typhoid fever diagnosis after controlled human infection identifies frequent asymptomatic cases and evidence of primary bacteraemia. J. Infect. 74, 358–366 (2017).
Blohmke, C. J. et al. Interferon-driven alterations of the host’s amino acid metabolism in the pathogenesis of typhoid fever. J. Exp. Med. 213, 1061–1077 (2016).
Darton, T. C. et al. Rapidly escalating hepcidin and associated serum iron starvation are features of the acute response to typhoid infection in humans. PLoS Negl. Trop. Dis. 9, e0004029 (2015).
Darton, T. C. et al. Identification of novel serodiagnostic signatures of typhoid fever using a Salmonella proteome array. Front. Microbiol. 8, 1794 (2017).
Blohmke, C. J. et al. Diagnostic host gene signature for distinguishing enteric fever from other febrile diseases. EMBO Mol. Med. 11, e10431 (2019).
Song, J., Gao, X. & Galán, J. E. Structure and function of the Salmonella Typhi chimaeric A2B5 typhoid toxin. Nature 499, 350–354 (2013).
Del Bel Belluz, L. et al. The typhoid toxin promotes host survival and the establishment of a persistent asymptomatic infection. PLoS Pathog. 12, e1005528 (2016).
den Bakker, H. C. et al. Genome sequencing reveals diversification of virulence factor content and possible host adaptation in distinct subpopulations of Salmonella enterica. BMC Genomics 12, 425 (2011).
Rodriguez-Rivera, L. D., Bowen, B. M., den Bakker, H. C., Duhamel, G. E. & Wiedmann, M. Characterization of the cytolethal distending toxin (typhoid toxin) in non-typhoidal Salmonella serovars. Gut Pathog. 7, 19 (2015).
Gibani, M. M. et al. Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model. Nat. Med. 25, 1082–1088 (2019).
Pitzer, V. E. et al. Predicting the impact of vaccination on the transmission dynamics of typhoid in South Asia: a mathematical modeling study. PLoS Negl. Trop. Dis. 8, e2642 (2014).
Saul, A., Smith, T. & Maire, N. Stochastic simulation of endemic Salmonella enterica serovar Typhi: the importance of long lasting immunity and the carrier state. PLoS ONE 8, e74097 (2013).
Gibani, M. M. et al. The impact of vaccination and prior exposure on stool shedding of Salmonella Typhi and Salmonella Paratyphi in 6 controlled human infection studies. Clin. Infect. Dis. 68, 1265–1273 (2019).
Marchello, C. S., Carr, S. D. & Crump, J. A. A systematic review on antimicrobial resistance among Salmonella Typhi worldwide. Am. J. Trop. Med. Hyg. 103, 2518–2527 (2020).
Britto, C. D., Wong, V. K., Dougan, G. & Pollard, A. J. A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid. PLoS Negl. Trop. Dis. 12, e0006779 (2018).
Bowe, F. et al. At least four percent of the Salmonella Typhimurium genome is required for fatal infection of mice. Infect. Immun. 66, 3372–3377 (1998).
Chau, T. T. et al. Antimicrobial drug resistance of Salmonella enterica serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob. Agents chemother. 51, 4315–4323 (2007).
Day, M. R. et al. Comparison of phenotypic and WGS-derived antimicrobial resistance profiles of Salmonella enterica serovars Typhi and Paratyphi. J. Antimicrob. Chemother. 73, 365–372 (2018).
Qamar, F. N. et al. Antimicrobial resistance in typhoidal Salmonella: Surveillance for Enteric Fever in Asia Project, 2016-2019. Clin. Infect. Dis. 71, S276–S284 (2020).
Akram, J. et al. Extensively drug-resistant (XDR) typhoid: evolution, prevention, and its management. Biomed. Res. Int. 2020, 6432580 (2020).
Posen, H. J. et al. Travel-associated extensively drug-resistant typhoid fever: a case series to inform management in non-endemic regions. J. Travel Med. 30, taac086 (2023).
Herdman, M. T. et al. Increasingly limited options for the treatment of enteric fever in travellers returning to England, 2014-2019: a cross-sectional analytical study. J. Med. Microbiol. 70, 001359 (2021).
Ashton, P. M. et al. The rapid emergence of Salmonella Typhi with decreased ciprofloxacin susceptibility following an increase in ciprofloxacin prescriptions in Blantyre, Malawi. Preprint at medRxiv https://doi.org/10.1101/2023.03.27.23287794 (2023).
Wijedoru, L., Mallett, S. & Parry, C. M. Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever. Cochrane Database Syst. Rev. 5, CD008892 (2017).
Azmatullah, A., Qamar, F. N., Thaver, D., Zaidi, A. K. & Bhutta, Z. A. Systematic review of the global epidemiology, clinical and laboratory profile of enteric fever. J. Glob. Health 5, 020407 (2015).
Aiemjoy, K. et al. Diagnostic value of clinical features to distinguish enteric fever from other febrile illnesses in Bangladesh, Nepal, and Pakistan. Clin. Infect. Dis. 71, S257–S265 (2020).
Andrews, J. R. et al. High rates of enteric fever diagnosis and lower burden of culture-confirmed disease in peri-urban and rural Nepal. J. Infect. Dis. 218, S214–S221 (2018).
Wain, J. et al. Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J. Clin. Microbiol. 36, 1683–1687 (1998).
Gilman, R. H., Terminel, M., Levine, M. M., Hernandez-Mendoza, P. & Hornick, R. B. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella Typhi in typhoid fever. Lancet 1, 1211–1213 (1975).
Mogasale, V., Ramani, E., Mogasale, V. V. & Park, J. What proportion of Salmonella Typhi cases are detected by blood culture? A systematic literature review. Ann. Clin. Microbiol. Antimicrob. 15, 32 (2016).
Wain, J. et al. Specimens and culture media for the laboratory diagnosis of typhoid fever. J. Infect. Dev. Ctries 2, 469–474 (2008).
Neupane, D. P., Dulal, H. P. & Song, J. Enteric fever diagnosis: current challenges and future directions. Pathogens 10, 410 (2021).
Tennant, S. M. et al. Detection of typhoidal and paratyphoidal Salmonella in blood by real-time polymerase chain reaction. Clin. Infect. Dis. 61, S241–S250 (2015).
Sapkota, J. et al. Comparative analysis of commercially available typhoid point-of-care tests: results of a prospective and hybrid retrospective multicenter diagnostic accuracy study in Kenya and Pakistan. J. Clin. Microbiol. 60, e0100022 (2022).
Charles, R. C. et al. Immunoproteomic analysis of antibody in lymphocyte supernatant in patients with typhoid fever in Bangladesh. Clin. Vaccin. Immunol. 21, 280–285 (2014).
Liang, L. et al. Immune profiling with a Salmonella Typhi antigen microarray identifies new diagnostic biomarkers of human typhoid. Sci. Rep. 3, 1043 (2013).
Andrews, J. R. et al. Plasma immunoglobulin a responses against 2 Salmonella Typhi antigens identify patients with typhoid fever. Clin. Infect. Dis. 68, 949–955 (2019).
Näsström, E. et al. Reproducible diagnostic metabolites in plasma from typhoid fever patients in Asia and Africa. eLife 6, e15651 (2017).
Aiemjoy, K. et al. Estimating typhoid incidence from community-based serosurveys: a multicohort study. Lancet Microbe 3, e578–e587 (2022).
Mylona, E. et al. The identification of enteric fever-specific antigens for population-based serosurveillance. J. Infect. Dis. https://doi.org/10.1093/infdis/jiad242 (2023).
Parry, C. M., Hien, T. T., Dougan, G., White, N. J. & Farrar, J. J. Typhoid fever. N. Engl. J. Med. 347, 1770–1782 (2002).
Stuart, B. M. & Pullen, R. L. Typhoid; clinical analysis of 360 cases. Arch. Intern. Med. 78, 629–661 (1946).
Crump, J. A., Sjölund-Karlsson, M., Gordon, M. A. & Parry, C. M. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin. Microbiol. Rev. 28, 901–937 (2015).
Hosoglu, S. et al. Risk factors for enteric perforation in patients with typhoid fever. Am. J. Epidemiol. 160, 46–50 (2004).
Birkhold, M. et al. Morbidity and mortality of typhoid intestinal perforation among children in sub-Saharan Africa 1995-2019: a scoping review. World J. Surg. 44, 2892–2902 (2020).
Neil, K. P. et al. A large outbreak of typhoid fever associated with a high rate of intestinal perforation in Kasese District, Uganda, 2008-2009. Clin. Infect. Dis. 54, 1091–1099 (2012).
Mogasale, V. et al. Case fatality rate and length of hospital stay among patients with typhoid intestinal perforation in developing countries: a systematic literature review. PLoS ONE 9, e93784 (2014).
Osuntokun, B. O., Bademosi, O., Ogunremi, K. & Wright, S. G. Neuropsychiatric manifestations of typhoid fever in 959 patients. Arch. Neurol. 27, 7–13 (1972).
Lutterloh, E. et al. Multidrug-resistant typhoid fever with neurologic findings on the Malawi-Mozambique border. Clin. Infect. Dis. 54, 1100–1106 (2012).
Britto, C. D. et al. Laboratory and molecular surveillance of paediatric typhoidal Salmonella in Nepal: antimicrobial resistance and implications for vaccine policy. PLoS Negl. Trop. Dis. 12, e0006408 (2018).
Britto, C., Pollard, A. J., Voysey, M. & Blohmke, C. J. An appraisal of the clinical features of pediatric enteric fever: systematic review and meta-analysis of the age-stratified disease occurrence. Clin. Infect. Dis. 64, 1604–1611 (2017).
Cruz Espinoza, L. M. et al. Occurrence of typhoid fever complications and their relation to duration of illness preceding hospitalization: a systematic literature review and meta-analysis. Clin. Infect. Dis. 69, S435–S448 (2019).
Al-Emran, H. M. et al. A multicountry molecular analysis of Salmonella enterica serovar typhi with reduced susceptibility to ciprofloxacin in sub-Saharan Africa. Clin. Infect. Dis. 62, S42–S46 (2016).
Levine, M. M., Black, R. E. & Lanata, C. Precise estimation of the numbers of chronic carriers of Salmonella Typhi in Santiago, Chile, an endemic area. J. Infect. Dis. 146, 724–726 (1982).
Khatri, N. S. et al. Gallbladder carriage of Salmonella paratyphi A may be an important factor in the increasing incidence of this infection in South Asia. Ann. Intern. Med. 150, 567–568 (2009).
Gonzalez-Escobedo, G., Marshall, J. M. & Gunn, J. S. Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state. Nat. Rev. Microbiol. 9, 9–14 (2011).
Crawford, R. W. et al. Gallstones play a significant role in Salmonella spp. gallbladder colonization and carriage. Proc. Natl Acad. Sci. USA 107, 4353–4358 (2010).
Dongol, S. et al. The microbiological and clinical characteristics of invasive Salmonella in gallbladders from cholecystectomy patients in Kathmandu, Nepal. PLoS ONE 7, e47342 (2012).
Schiøler, H., Christiansen, E. D., Høybye, G., Rasmussen, S. N. & Greibe, J. Biliary calculi in chronic Salmonella carriers and healthy controls: a controlled study. Scand. J. Infect. Dis. 15, 17–19 (1983).
Olsen, S. J. et al. Outbreaks of typhoid fever in the United States, 1960-99. Epidemiol. Infect. 130, 13–21 (2003).
Bokkenheuser, V. Detection of typhoid carriers. Am. J. Public. Health Nations Health 54, 477–486 (1964).
Avendano, A. et al. Duodenal string cultures: practicality and sensitivity for diagnosing enteric fever in children. J. Infect. Dis. 153, 359–362 (1986).
Hoffman, S. A., Sikorski, M. J. & Levine, M. M. Chronic Salmonella Typhi carriage at sites other than the gallbladder. PLoS Negl. Trop. Dis. 17, e0011168 (2023).
Lin, F. Y. et al. Restaurant-associated outbreak of typhoid fever in Maryland: identification of carrier facilitated by measurement of serum Vi antibodies. J. Clin. Microbiol. 26, 1194–1197 (1988).
Gupta, A. et al. Evaluation of community-based serologic screening for identification of chronic Salmonella Typhi carriers in Vietnam. Int. J. Infect. Dis. 10, 309–314 (2006).
Ferreccio, C. et al. The detection of chronic Salmonella Typhi carriers: a practical method applied to food handlers [Spanish]. Rev. Med. Chil. 118, 33–37 (1990).
Lanata, C. F. et al. Vi serology in detection of chronic Salmonella Typhi carriers in an endemic area. Lancet 2, 441–443 (1983).
Thompson, L. J. et al. Transcriptional response in the peripheral blood of patients infected with Salmonella enterica serovar Typhi. Proc. Natl Acad. Sci. USA 106, 22433–22438 (2009).
Tran Vu Thieu, N. et al. An evaluation of purified Salmonella Typhi protein antigens for the serological diagnosis of acute typhoid fever. J. Infect. 75, 104–114 (2017).
Näsström, E. et al. Diagnostic metabolite biomarkers of chronic typhoid carriage. PLoS Negl. Trop. Dis. 12, e0006215 (2018).
Gauld, J. S., Hu, H., Klein, D. J. & Levine, M. M. Typhoid fever in Santiago, Chile: insights from a mathematical model utilizing venerable archived data from a successful disease control program. PLoS Negl. Trop. Dis. 12, e0006759 (2018).
Ng’eno, E. et al. Dynamic incidence of typhoid fever over a 10-year period (2010-2019) in Kibera, an Urban Informal Settlement in Nairobi, Kenya. Am. J. Trop. Med. Hyg. 109, 22–31 (2023).
Sikorski, M. J. & Levine, M. M. Reviving the “Moore swab”: a classic environmental surveillance tool involving filtration of flowing surface water and sewage water to recover typhoidal Salmonella bacteria. Appl. Environ. Microbiol. 86, e00060-20 (2020).
Kim, C. et al. Associations of water, sanitation, and hygiene with typhoid fever in case-control studies: a systematic review and meta-analysis. BMC Infect. Dis. 23, 562 (2023).
Stanaway, J. D., Atuhebwe, P. L., Luby, S. P. & Crump, J. A. Assessing the feasibility of typhoid elimination. Clin. Infect. Dis. 71, S179–S184 (2020).
Hejfec, L. B. Results of the study of typhoid vaccines in four controlled field trials in the USSR. Bull. World Health Organ. 32, 1–14 (1965).
WHO. Typhoid vaccines: WHO position paper. Wkly Epidemiol. Rec. 83, 49–59 (2008).
Engels, E. A., Falagas, M. E., Lau, J. & Bennish, M. L. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 316, 110–116 (1998).
Milligan, R., Paul, M., Richardson, M. & Neuberger, A. Vaccines for preventing typhoid fever. Cochrane Database Syst. Rev. 5, CD001261 (2018).
Goldblatt, D. Conjugate vaccines. Clin. Exp. Immunol. 119, 1–3 (2000).
WHO. Typhoid vaccines: WHO position paper – March 2018. Wkly Epidemiol. Rec. 93, 153–172 (2018).
Mohan, V. K. et al. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin. Infect. Dis. 61, 393–402 (2015).
Jin, C. et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet 390, 2472–2480 (2017).
Meiring, J. E., Giubilini, A., Savulescu, J., Pitzer, V. E. & Pollard, A. J. Generating the evidence for typhoid vaccine introduction: considerations for global disease burden estimates and vaccine testing through human challenge. Clin. Infect. Dis. 69, S402–S407 (2019).
Nampota, N. et al. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months through 12 years in Malawi: results from a randomised, double-blind, controlled trial. Lancet Glob. Health 10, e1326–e1335 (2022).
Sirima, S. B. et al. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. Int. J. Infect. Dis. 102, 517–523 (2021).
Patel, P. D. et al. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. N. Engl. J. Med. 385, 1104–1115 (2021).
Meiring, J. E. et al. Typhoid Vaccine Acceleration Consortium Malawi: a phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi. Clin. Infect. Dis. 68, S50–S58 (2019).
Colin-Jones, R. et al. Logistics of implementing a large-scale typhoid vaccine trial in Kathmandu, Nepal. Clin. Infect. Dis. 68, S138–S145 (2019).
Shakya, M. et al. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. N. Engl. J. Med. 381, 2209–2218 (2019).
Patel, P. et al. Efficacy of typhoid conjugate vaccine: final analysis of a four-year, randomised controlled trial in Malawian children. Preprint at https://ssrn.com/abstract=4411421 (2023).
Theiss-Nyland, K. et al. Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection among Bangladeshi children: a protocol for a phase IIIb trial. Clin. Infect. Dis. 68, S74–S82 (2019).
Qadri, F. et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet 398, 675–684 (2021).
Khanam, F. et al. Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis. eClinicalMedicine 58, 101925 (2023).
Hoffman, S. A. et al. Programmatic effectiveness of a pediatric typhoid conjugate vaccine campaign in Navi Mumbai, India. Clin. Infect. Dis. 77, 138–144 (2023).
Yousafzai, M. T. et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. Lancet Glob. Health 9, e1154–e1162 (2021).
Lightowler, M. S. et al. Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: a matched case control study. Vaccine 40, 4199–4210 (2022).
Nampota-Nkomba, N., Carey, M. E., Jamka, L. P., Fecteau, N. & Neuzil, K. M. Using typhoid conjugate vaccines to prevent disease, promote health equity, and counter drug-resistant typhoid fever. Open. Forum Infect. Dis. 10, S6–S12 (2023).
Khanam, F., Ross, A. G., McMillan, N. A. J. & Qadri, F. Toward typhoid fever elimination. Int. J. Infect. Dis. 119, 41–43 (2022).
Nga, T. V. T., Duy, P. T., Lan, N. P. H., Chau, N. V. V. & Baker, S. The control of typhoid fever in Vietnam. Am. J. Trop. Med. Hyg. 99, 72–78 (2018).
Browne, A. J. et al. Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis. BMC Med. 18, 1 (2020).
Bhutta, Z. A. Impact of age and drug resistance on mortality in typhoid fever. Arch. Dis. Child. 75, 214–217 (1996).
Parry, C. M. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. Trans. R. Soc. Trop. Med. Hyg. 98, 413–422 (2004).
Nabarro, L. E. et al. British Infection Association guidelines for the diagnosis and management of enteric fever in England. J. Infect. 84, 469–489 (2022).
Dolecek, C., Pokharel, S., Basnyat, B. & Olliaro, P. Antibiotics for typhoid fever. in The selection and use of essential medicines. WHO Technical Report Series No. 1021. 19–26 https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1 (WHO, 2019).
Carey, M. E. et al. Spontaneous emergence of azithromycin resistance in independent lineages of Salmonella Typhi in Northern India. Clin. Infect. Dis. 72, e120–e127 (2021).
Duy, P. T. et al. The emergence of azithromycin-resistant Salmonella Typhi in Nepal. JAC Antimicrob. Resist. 2, dlaa109 (2020).
Effa, E. E. & Bukirwa, H. Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 4, CD006083 (2008).
Effa, E. E. et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst. Rev. 2011, CD004530 (2011).
Eliakim-Raz, N. et al. Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 70, 979–996 (2015).
Qamar, F. N. et al. Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: a matched case-control study. Lancet Infect. Dis. 18, 1368–1376 (2018).
Argimón, S. et al. Circulation of third-generation cephalosporin resistant Salmonella Typhi in Mumbai, India. Clin. Infect. Dis. 74, 2234–2237 (2022).
Samajpati, S., Pragasam, A. K., Mandal, S., Balaji, V. & Dutta, S. Emergence of ceftriaxone resistant Salmonella enterica serovar Typhi in Eastern India. Infect., Genet. Evolution 96, 105093 (2021).
Qureshi, S. et al. Response of extensively drug resistant Salmonella Typhi to treatment with meropenem and azithromycin, in Pakistan. PLoS Negl. Trop. Dis. 14, e0008682 (2020).
Van Be Bay, P. et al. Quantitative bacterial counts in the bone marrow of Vietnamese patients with typhoid fever. Trans. R. Soc. Trop. Med. Hyg. 116, 736–744 (2022).
Pascual, A., Conejo, M. C., García, I. & Perea, E. J. Factors affecting the intracellular accumulation and activity of azithromycin. J. Antimicrob. Chemother. 35, 85–93 (1995).
Zmora, N. et al. Open label comparative trial of mono versus dual antibiotic therapy for typhoid fever in adults. PLoS Negl. Trop. Dis. 12, e0006380 (2018).
Giri, A. et al. Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol. Wellcome Open. Res. 6, 207 (2021).
Butler, T. et al. Typhoid fever complicated by intestinal perforation: a persisting fatal disease requiring surgical management. Rev. Infect. Dis. 7, 244–256 (1985).
Hoffman, S. L. et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N. Engl. J. Med. 310, 82–88 (1984).
Contopoulos-Ioannidis, D. G. & Ioannidis, J. P. Claims for improved survival from systemic corticosteroids in diverse conditions: an umbrella review. Eur. J. Clin. Invest. 42, 233–244 (2012).
McCann, N., Scott, P., Parry, C. M. & Brown, M. Antimicrobial agents for the treatment of enteric fever chronic carriage: a systematic review. PLoS ONE 17, e0272043 (2022).
Luthra, K. et al. A review of the economic evidence of typhoid fever and typhoid vaccines. Clin. Infect. Dis. 68, S83–S95 (2019).
Riewpaiboon, A. et al. Cost of illness due to typhoid fever in Pemba, Zanzibar, East Africa. J. Health Popul. Nutr. 32, 377–385 (2014).
Bahl, R. et al. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J. Health Popul. Nutr. 22, 304–310 (2004).
Kaljee, L. M. et al. Social and economic burden associated with typhoid fever in Kathmandu and surrounding areas: a qualitative study. J. Infect. Dis. 218, S243–S249 (2018).
Limani, F. et al. Estimating the economic burden of typhoid in children and adults in Blantyre, Malawi: a costing cohort study. PLoS ONE 17, e0277419 (2022).
Mejia, N. et al. Typhoid and paratyphoid cost of illness in Nepal: patient and health facility costs from the Surveillance for Enteric Fever in Asia Project II. Clin. Infect. Dis. 71, S306–S318 (2020).
Mejia, N. et al. Typhoid and paratyphoid cost of illness in Bangladesh: patient and health facility costs from the Surveillance for Enteric Fever in Asia Project II. Clin. Infect. Dis. 71, S293–S305 (2020).
Mejia, N. et al. Typhoid and paratyphoid cost of illness in Pakistan: patient and health facility costs from the Surveillance for Enteric Fever in Asia Project II. Clin. Infect. Dis. 71, S319–S335 (2020).
Bilcke, J. et al. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. Lancet Infect. Dis. 19, 728–739 (2019).
Seyi-Olajide, J. O. et al. Catastrophic healthcare expenditure from typhoid perforation in children in Nigeria. Surg. Infect. 21, 586–591 (2020).
Kumar, D. et al. Cost of illness due to severe enteric fever in India. J. Infect. Dis. 224, S540–S547 (2021).
Malik A. Comparison of cost of illness of extensively drug resistant (XDR) vs. non-XDR typhoid fever in Pakistan: policy implications for typhoid vaccine. Coalition Against Typhoid Conference https://www.coalitionagainsttyphoid.org/wp-content/uploads/2019/04/ABSTRACT9_Pres5_Malik.pdf (2019).
Birkhold, M., Mwisongo, A., Pollard, A. J. & Neuzil, K. M. Typhoid conjugate vaccine in Africa and Asia: status of clinical evaluation and vaccine introduction. J. Infect. Dis. https://doi.org/10.1093/infdis/jiab449 (2021).
WHO. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations. Wkly Epidemiol. Rec. 97, 261–276 (2022).
Gavi the Vaccine Alliance. Typhoid conjugate vaccine (TCV) support. Gavi https://www.gavi.org/types-support/vaccine-support/typhoid (2023).
Lo, N. C. et al. Comparison of strategies and incidence thresholds for Vi conjugate vaccines against typhoid fever: a cost-effectiveness modeling study. J. Infect. Dis. 218, S232–S242 (2018).
Burrows, H. et al. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness. Vaccine 41, 965–975 (2023).
Chauhan, A. S. et al. Cost effectiveness of typhoid vaccination in India. Vaccine 39, 4089–4098 (2021).
Ryckman, T. et al. Comparison of strategies for typhoid conjugate vaccine introduction in India: a cost-effectiveness modeling study. J. Infect. Dis. 224, S612–S624 (2021).
Carey, M. E., McCann, N. S. & Gibani, M. M. Typhoid fever control in the 21st century: where are we now? Curr. Opin. Infect. Dis. 35, 424–430 (2022).
MacLennan, C. A., Stanaway, J., Grow, S., Vannice, K. & Steele, A. D. Salmonella combination vaccines: moving beyond typhoid. Open. Forum Infect. Dis. 10, S58–S66 (2023).
Shakya, M. et al. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob. Health 9, e1561–e1568 (2021).
Batool, R. et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: a case-control study. Vaccine 39, 5858–5865 (2021).
Juel, H. B. et al. Salmonella Typhi bactericidal antibodies reduce disease severity but do not protect against typhoid fever in a controlled human infection model. Front. Immunol. 8, 1916 (2017).
Jones, E. et al. A Salmonella Typhi controlled human infection study for assessing correlation between bactericidal antibodies and protection against infection induced by typhoid vaccination. Microorganisms 9, 1394 (2021).
Jin, C. et al. Treatment responses to azithromycin and ciprofloxacin in uncomplicated Salmonella Typhi infection: a comparison of clinical and microbiological data from a controlled human infection model. PLoS Negl. Trop. Dis. 13, e0007955 (2019).
Jin, C. et al. Vi-specific serological correlates of protection for typhoid fever. J. Exp. Med. 218, e20201116 (2021).
Dahora, L. C. et al. IgA and IgG1 specific to Vi polysaccharide of Salmonella typhi correlate with protection status in a typhoid fever controlled human infection model. Front. Immunol. 10, 2582 (2019).
Cross, D. L. et al. Vi-vaccinations induce heterogeneous plasma cell responses that associate with protection from typhoid fever. Front. Immunol. 11, 574057 (2020).
Author information
Authors and Affiliations
Contributions
Introduction (M.A.G. and J.E.M.); Epidemiology (M.A.G., J.A.C., B.B., F.Q., S.K., F.K. and J.E.M.); Mechanisms/pathophysiology (M.A.G., K.E.H., A.J.P. and J.E.M.); Diagnosis, screening and prevention (M.A.G., R.C.C., C.M.P. and J.E.M.); Management (M.A.G., B.B., F.Q., C.M.P., F.K. and J.E.M.); Quality of life (M.A.G., V.E.P., J.E.M. and F.D.); Outlook (M.A.G., E.M. A.J.P., K.M.N., V.E.P. and J.E.M.); Overview of the Primer (J.E.M. and M.A.G.).
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Disease Primers thanks S. Luby and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Meiring, J.E., Khanam, F., Basnyat, B. et al. Typhoid fever. Nat Rev Dis Primers 9, 71 (2023). https://doi.org/10.1038/s41572-023-00480-z
Accepted:
Published:
DOI: https://doi.org/10.1038/s41572-023-00480-z
This article is cited by
-
Tackling non-typhoidal Salmonella with humility
Nature Microbiology (2024)
